Free Trial
NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Pliant Therapeutics logo
$1.25 +0.05 (+3.75%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$1.25 0.00 (0.00%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Key Stats

Today's Range
$1.18
$1.27
50-Day Range
$1.16
$1.69
52-Week Range
$1.10
$16.10
Volume
1.12 million shs
Average Volume
1.18 million shs
Market Capitalization
$76.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.31
Consensus Rating
Hold

Company Overview

Pliant Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

PLRX MarketRank™: 

Pliant Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 208th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 12 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pliant Therapeutics has received no research coverage in the past 90 days.

  • Read more about Pliant Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.64) to ($3.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pliant Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pliant Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pliant Therapeutics has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pliant Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.95% of the float of Pliant Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pliant Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pliant Therapeutics has recently decreased by 14.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pliant Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pliant Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.95% of the float of Pliant Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pliant Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pliant Therapeutics has recently decreased by 14.29%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.00% of the stock of Pliant Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pliant Therapeutics' insider trading history.
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Stock News Headlines

Pliant Therapeutics Provides Update on BEACON-IPF
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Pliant Therapeutics announces workforce reduction
See More Headlines

PLRX Stock Analysis - Frequently Asked Questions

Pliant Therapeutics' stock was trading at $13.17 at the beginning of 2025. Since then, PLRX stock has decreased by 90.5% and is now trading at $1.2450.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its earnings results on Monday, March, 3rd. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.17.

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/03/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.31
High Stock Price Target
$45.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+969.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$210.30 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.58 million
Price / Cash Flow
N/A
Book Value
$5.00 per share
Price / Book
0.25

Miscellaneous

Free Float
56,475,000
Market Cap
$76.43 million
Optionable
Optionable
Beta
1.30
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:PLRX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners